EE89 Cost-Effectiveness Analysis of Onasemnogene Abeparvovec-Xioi (Zolgensma®) and Best Supportive Care Treatment for Spinal Muscular Atrophy I in the Netherlands With Early-Treatment Scenario
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.360
https://www.valueinhealthjournal.com/article/S1098-3015(23)03490-3/fulltext
Title :
EE89 Cost-Effectiveness Analysis of Onasemnogene Abeparvovec-Xioi (Zolgensma®) and Best Supportive Care Treatment for Spinal Muscular Atrophy I in the Netherlands With Early-Treatment Scenario
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03490-3&doi=10.1016/j.jval.2023.09.360
First page :
Section Title :
Open access? :
No
Section Order :
12385